Denosumab beta-cell preservation
City of Hope Medical Center (investigator-led); repurposed Prolia/Xgeva (denosumab)
A repurposing hypothesis around denosumab, the RANKL-targeting osteoporosis drug, to protect or improve beta-cell function in early T1D. A single phase 1/2 trial is still recruiting as of July 2026, and human T1D efficacy is unproven.
The scorecard
The registry and funder rationale cite lab evidence that the RANKL pathway may affect beta-cell health, but no T1D efficacy result is posted.[1]
Durability is unknown; the current trial tests intermittent dosing over time rather than a proven lasting beta-cell rescue.[2]
Denosumab is approved for other diseases, but its risk-benefit in young or early T1D populations is unproven and requires trial monitoring.[1]
The trial enrols adults only (women 18-50, men 21-50) who are 1-5 years from diagnosis and still have residual C-peptide of at least 0.2 nmol/L (0.6 ng/mL) — not children, and not long-established disease.[1]
Still phase 1/2 and still recruiting as of July 2026; no diabetes approval and no phase 3 program.[1]
The full picture
Denosumab is not a diabetes drug today. The reason it belongs on the horizon list is mechanism: RANKL signaling may influence beta-cell health, and denosumab already has a known clinical pharmacology in other indications. The trial will decide whether that biology translates into safer glucose control or preserved beta-cell function in people with early T1D.
Where it actually stands (July 2026)
There is exactly one trial, and it is still enrolling — not reporting. NCT06524960, sponsored by City of Hope Medical Center, is a phase 1/2 study of 45 adults randomised 2:1 to denosumab or placebo: 60 mg injected under the skin every three months, four doses in total. It is recruiting at three US sites — the University of Alabama at Birmingham, City of Hope in Duarte, California, and Indiana University. Primary completion is scheduled for October 2027.
To take part you must be an adult (women 18–50, men 21–50), be positive for at least one T1D autoantibody, be between one and five years from diagnosis, and still be making some of your own insulin — a non-fasting C-peptide of at least 0.2 nmol/L (0.6 ng/mL). That last criterion is the point: this is a preservation strategy aimed at people who still have beta cells left to protect. It is not being tested in children, and it is not being tested in long-established T1D.
No efficacy results have been posted, and denosumab was not presented as a T1D result at ADA 2026. Anyone telling you this drug preserves beta cells in humans is ahead of the evidence — the question is open, and the earliest a first answer could arrive is 2027.
Coming soon
ETA · Phase 1/2 still recruiting as of July 2026 at three US sites; primary completion October 2027. No human T1D efficacy result exists yet.
Sources